Exelixis, Inc. (EXEL)

$35.93

-0.52

(-1.43%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Performance

  • $35.58
    $36.73
    $35.93
    downward going graph

    0.97%

    Downside

    Day's Volatility :3.13%

    Upside

    2.18%

    downward going graph
  • $19.20
    $36.72
    $35.93
    downward going graph

    46.56%

    Downside

    52 Weeks Volatility :47.71%

    Upside

    2.15%

    downward going graph

Returns

PeriodExelixis, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
41.66%
-6.1%
0.0%
6 Months
79.2%
1.2%
0.0%
1 Year
68.67%
12.2%
0.0%
3 Years
115.55%
10.8%
-21.2%

Highlights

Market Capitalization
10.4B
Book Value
$7.96
Earnings Per Share (EPS)
1.55
PE Ratio
23.52
PEG Ratio
2.64
Wall Street Target Price
31.83
Profit Margin
22.43%
Operating Margin TTM
34.81%
Return On Assets TTM
12.81%
Return On Equity TTM
20.2%
Revenue TTM
2.1B
Revenue Per Share TTM
7.03
Quarterly Revenue Growth YOY
14.299999999999999%
Gross Profit TTM
1.6B
EBITDA
636.0M
Diluted Eps TTM
1.55
Quarterly Earnings Growth YOY
121.7
EPS Estimate Current Year
1.95
EPS Estimate Next Year
1.96
EPS Estimate Current Quarter
0.35
EPS Estimate Next Quarter
0.33

Analyst Recommendation

Buy
    76%Buy
    19%Hold
    3%Sell
Based on 26 Wall street analysts offering stock ratings for Exelixis, Inc.(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
21
21
Hold
5
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Downside of 11.41%

Current $35.93
Target $31.83

Company Financials

FY20Y/Y Change
Revenue
987.5M
↑ 2.04%
Net Income
111.8M
↓ 65.18%
Net Profit Margin
11.32%
↓ 21.85%
FY21Y/Y Change
Revenue
1.4B
↑ 45.31%
Net Income
231.1M
↑ 106.71%
Net Profit Margin
16.1%
↑ 4.78%
FY21Y/Y Change
Revenue
1.4B
↑ 45.31%
Net Income
231.1M
↑ 106.71%
Net Profit Margin
16.1%
↑ 4.78%
FY22Y/Y Change
Revenue
1.6B
↑ 12.27%
Net Income
182.3M
↓ 21.11%
Net Profit Margin
11.31%
↓ 4.79%
FY22Y/Y Change
Revenue
1.6B
↑ 12.27%
Net Income
182.3M
↓ 21.11%
Net Profit Margin
11.31%
↓ 4.79%
FY23Y/Y Change
Revenue
1.8B
↑ 13.6%
Net Income
207.8M
↑ 13.98%
Net Profit Margin
11.35%
↑ 0.04%
Q2 FY23Q/Q Change
Revenue
469.8M
↑ 14.94%
Net Income
81.2M
↑ 102.8%
Net Profit Margin
17.28%
↑ 7.49%
Q3 FY23Q/Q Change
Revenue
471.9M
↑ 0.44%
Net Income
1.0M
↓ 98.72%
Net Profit Margin
0.22%
↓ 17.06%
Q4 FY23Q/Q Change
Revenue
479.7M
↑ 1.64%
Net Income
85.5M
↑ 8114.99%
Net Profit Margin
17.83%
↑ 17.61%
Q1 FY24Q/Q Change
Revenue
425.2M
↓ 11.35%
Net Income
37.3M
↓ 56.36%
Net Profit Margin
8.78%
↓ 9.05%
Q2 FY24Q/Q Change
Revenue
637.2M
↑ 49.84%
Net Income
226.1M
↑ 505.93%
Net Profit Margin
35.49%
↑ 26.71%
Q3 FY24Q/Q Change
Revenue
539.5M
↓ 15.32%
Net Income
118.0M
↓ 47.83%
Net Profit Margin
21.87%
↓ 13.62%
FY20Y/Y Change
Total Assets
2.1B
↑ 13.35%
Total Liabilities
258.2M
↑ 29.3%
FY21Y/Y Change
Total Assets
2.6B
↑ 22.41%
Total Liabilities
405.6M
↑ 57.08%
FY21Y/Y Change
Total Assets
2.6B
↑ 22.41%
Total Liabilities
405.6M
↑ 57.08%
FY22Y/Y Change
Total Assets
3.1B
↑ 17.4%
Total Liabilities
583.1M
↑ 43.74%
FY22Y/Y Change
Total Assets
3.1B
↑ 17.4%
Total Liabilities
583.1M
↑ 43.74%
FY23Y/Y Change
Total Assets
2.9B
↓ 4.2%
Total Liabilities
678.4M
↑ 16.36%
Q2 FY23Q/Q Change
Total Assets
3.1B
↓ 0.03%
Total Liabilities
614.5M
↑ 4.47%
Q3 FY23Q/Q Change
Total Assets
3.0B
↓ 5.27%
Total Liabilities
629.3M
↑ 2.4%
Q4 FY23Q/Q Change
Total Assets
2.9B
↓ 1.16%
Total Liabilities
678.4M
↑ 7.81%
Q1 FY24Q/Q Change
Total Assets
2.8B
↓ 4.71%
Total Liabilities
675.7M
↓ 0.4%
Q2 FY24Q/Q Change
Total Assets
2.8B
↓ 1.09%
Total Liabilities
653.4M
↓ 3.31%
Q3 FY24Q/Q Change
Total Assets
3.0B
↑ 6.75%
Total Liabilities
684.9M
↑ 4.82%
FY18Y/Y Change
Operating Cash Flow
415.7M
↑ 151.02%
Investing Cash Flow
-297.9M
↓ 909.48%
Financing Cash Flow
9.7M
↓ 105.7%
FY19Y/Y Change
Operating Cash Flow
527.0M
↑ 26.76%
Investing Cash Flow
-587.2M
↑ 97.16%
Financing Cash Flow
12.6M
↑ 29.53%
FY20Y/Y Change
Operating Cash Flow
209.0M
↓ 60.34%
Investing Cash Flow
-131.2M
↓ 77.66%
Financing Cash Flow
-25.1M
↓ 300.21%
FY21Y/Y Change
Operating Cash Flow
400.8M
↑ 91.79%
Investing Cash Flow
-42.9M
↓ 67.32%
Financing Cash Flow
-14.8M
↓ 41.11%
FY22Y/Y Change
Operating Cash Flow
362.6M
↓ 9.53%
Investing Cash Flow
-524.4M
↑ 1122.87%
Financing Cash Flow
586.0K
↓ 103.96%
Q2 FY23Q/Q Change
Operating Cash Flow
121.0M
↑ 43.33%
Investing Cash Flow
-73.8M
↑ 48.78%
Financing Cash Flow
-124.8M
↓ 2821.15%
Q3 FY23Q/Q Change
Operating Cash Flow
117.4M
↓ 2.98%
Investing Cash Flow
34.7M
↓ 147.01%
Financing Cash Flow
-219.7M
↑ 76.03%

Technicals Summary

Sell

Neutral

Buy

Exelixis, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exelixis, Inc.
Exelixis, Inc.
27.89%
79.2%
68.67%
115.55%
119.98%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.91%
-22.62%
-5.64%
15.07%
102.66%
Biontech Se
Biontech Se
4.66%
25.97%
22.38%
-67.3%
441.77%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-11.7%
68.83%
59.14%
40.17%
115.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.95%
4.52%
33.38%
145.68%
112.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exelixis, Inc.
Exelixis, Inc.
23.52
23.52
2.64
1.95
0.2
0.13
NA
7.96
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exelixis, Inc.
Exelixis, Inc.
Buy
$10.4B
119.98%
23.52
22.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
102.66%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
441.77%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
115.51%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$118.9B
112.25%
32.84
-4.51%

Insights on Exelixis, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 637.17M → 539.54M (in $), with an average decrease of 15.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 226.11M → 117.97M (in $), with an average decrease of 47.8% per quarter

Institutional Holdings

  • BlackRock Inc

    11.73%

  • Vanguard Group Inc

    10.26%

  • Farallon Capital Management, L.L.C.

    8.90%

  • Renaissance Technologies Corp

    5.38%

  • State Street Corp

    4.41%

  • LSV Asset Management

    2.84%

Company Information

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.

Organization
Exelixis, Inc.
Employees
1310
CEO
Dr. Stelios Papadopoulos Ph.D.
Industry
Health Technology

FAQs